全文获取类型
| 收费全文 | 75028篇 |
| 免费 | 4800篇 |
| 国内免费 | 333篇 |
专业分类
| 耳鼻咽喉 | 862篇 |
| 儿科学 | 1756篇 |
| 妇产科学 | 1569篇 |
| 基础医学 | 11155篇 |
| 口腔科学 | 3654篇 |
| 临床医学 | 6590篇 |
| 内科学 | 17169篇 |
| 皮肤病学 | 1963篇 |
| 神经病学 | 6785篇 |
| 特种医学 | 1684篇 |
| 外科学 | 7401篇 |
| 综合类 | 348篇 |
| 现状与发展 | 1篇 |
| 一般理论 | 45篇 |
| 预防医学 | 7452篇 |
| 眼科学 | 1225篇 |
| 药学 | 5485篇 |
| 中国医学 | 417篇 |
| 肿瘤学 | 4600篇 |
出版年
| 2024年 | 88篇 |
| 2023年 | 756篇 |
| 2022年 | 1593篇 |
| 2021年 | 2849篇 |
| 2020年 | 1745篇 |
| 2019年 | 2485篇 |
| 2018年 | 2886篇 |
| 2017年 | 2024篇 |
| 2016年 | 2122篇 |
| 2015年 | 2545篇 |
| 2014年 | 3207篇 |
| 2013年 | 4001篇 |
| 2012年 | 6110篇 |
| 2011年 | 6568篇 |
| 2010年 | 3408篇 |
| 2009年 | 2915篇 |
| 2008年 | 4757篇 |
| 2007年 | 4765篇 |
| 2006年 | 4309篇 |
| 2005年 | 3882篇 |
| 2004年 | 3481篇 |
| 2003年 | 3024篇 |
| 2002年 | 2693篇 |
| 2001年 | 816篇 |
| 2000年 | 789篇 |
| 1999年 | 746篇 |
| 1998年 | 491篇 |
| 1997年 | 416篇 |
| 1996年 | 301篇 |
| 1995年 | 273篇 |
| 1994年 | 257篇 |
| 1993年 | 195篇 |
| 1992年 | 370篇 |
| 1991年 | 317篇 |
| 1990年 | 313篇 |
| 1989年 | 284篇 |
| 1988年 | 219篇 |
| 1987年 | 189篇 |
| 1986年 | 204篇 |
| 1985年 | 198篇 |
| 1984年 | 139篇 |
| 1983年 | 120篇 |
| 1982年 | 85篇 |
| 1981年 | 68篇 |
| 1980年 | 94篇 |
| 1979年 | 125篇 |
| 1978年 | 130篇 |
| 1975年 | 91篇 |
| 1974年 | 92篇 |
| 1973年 | 95篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
21.
22.
23.
24.
Oliveira Gon&#;alves Ana Sofia Panteli Dimitra Neeb Lars Kurth Tobias Aigner Annette 《The European journal of health economics》2022,23(1):47-57
The European Journal of Health Economics - The aims of this study were to assess whether there is a conceptual overlap between the questionnaires HIT-6 and EQ-5D and to develop a mapping algorithm... 相似文献
25.
Paola Gilsanz Maria M. Corrada Claudia H. Kawas Elizabeth Rose Mayeda M. Maria Glymour Charles P. Quesenberry Catherine Lee Rachel A. Whitmer 《Alzheimer's & dementia》2019,15(4):497-505
Introduction
Little is known about dementia incidence in diverse populations of oldest-old, the age group with highest dementia incidence.Methods
Incident dementia diagnoses from 1/1/2010 to 9/30/2015 were abstracted from medical records for 2350 members of an integrated health care system in California (n = 1702 whites, n = 375 blacks, n = 105 Latinos, n = 168 Asians) aged ≥90 in 2010. We estimated race/ethnicity-specific age-adjusted dementia incidence rates and implemented Cox proportional hazards models and Fine and Gray competing risk of death models adjusted for demographics and comorbidities in midlife and late-life.Results
Dementia incidence rates (n = 771 cases) were lowest among Asians (89.9/1000 person-years), followed by whites (96.9/1000 person-years), Latinos (105.8/1000 person-years), and blacks (121.5/1000 person-years). Cox regression and competing risk models estimated 28% and 36% higher dementia risk for blacks versus whites adjusting for demographics and comorbidities.Discussion
Patterns of racial/ethnic disparities in dementia seen in younger older adults continue after the age of 90 years, though smaller in magnitude. 相似文献26.
Luis Veloza Cristina Teixido Natalia Castrejon Fina Climent Ana Carri Marta Marginet Davide Soldini Blanca Gonzlez‐Farr Inmaculada Ribera‐Cortada Armando Lopez‐Guillermo Eva Gonzlez‐Barca Adriana Sierra Mileyka Herrera Cndida Gmez Adriana Garcia Olga Balagu Elias Campo Antonio Martinez 《Histopathology》2019,75(6):799-812
27.
Megan L. Robbins Robert C. Wright Ana María López Karen Weihs 《Journal of psychosocial oncology》2019,37(2):160-177
AbstractObjectives: This study examined word use as an indicator of interpersonal positive reframing in daily conversations of couples coping with breast cancer and as a predictor of stress.Design: The Electronically Activated Recorder (EAR) and Linguistic Inquiry and Word Count (LIWC) were used to examine naturally occurring word use conceptually linked to positive reframing (positive emotion, negative emotion, and cognitive processing words).Sample: Fifty-two couples coping with breast cancer.Methods: Couples wore the EAR, a device participants wear, that audio-recorded over one weekend (>16,000 sound files), and completed self-reports of positive reframing (COPE) and stress (Perceived Stress Scale). LIWC, a software program, measured word use.Findings: Both partners’ word use (i.e., positive emotion and cognitive processing words) was associated with their own reported positive reframing, and spouses’ word use was also indicative of patients’ positive reframing. Results also revealed that, in general, words indicating positive reframing predicted lower levels of stress.Conclusions: Findings supported the hypothesis that partners—and particularly spouses of breast cancer patients—may assist each other’s coping by positively reframing the cancer experience and other negative experiences in conversation. 相似文献
28.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献29.
Toshiro Hara Rony Chanoch-Myers Nathan D. Mathewson Chad Myskiw Lyla Atta Lillian Bussema Stephen W. Eichhorn Alissa C. Greenwald Gabriela S. Kinker Christopher Rodman L. Nicolas Gonzalez Castro Hiroaki Wakimoto Orit Rozenblatt-Rosen Xiaowei Zhuang Jean Fan Tony Hunter Inder M. Verma Kai W. Wucherpfennig Itay Tirosh 《Cancer cell》2021,39(6):779-792.e11
- Download : Download high-res image (228KB)
- Download : Download full-size image
30.